Cargando…

Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance

Antimicrobial resistance (AMR) is a global health problem that causes more than 1.27 million deaths annually; therefore, it is urgent to focus efforts on solving or reducing this problem. The major causes of AMR are the misuse of antibiotics and antimicrobials in agriculture, veterinary medicine, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedraza-Sánchez, Sigifredo, Cruz-González, Adrián, Palmeros-Rojas, Oscar, Gálvez-Romero, José Luis, Bellanti, Joseph A., Torres, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880058/
https://www.ncbi.nlm.nih.gov/pubmed/36713426
http://dx.doi.org/10.3389/fimmu.2022.987231
_version_ 1784878830187446272
author Pedraza-Sánchez, Sigifredo
Cruz-González, Adrián
Palmeros-Rojas, Oscar
Gálvez-Romero, José Luis
Bellanti, Joseph A.
Torres, Martha
author_facet Pedraza-Sánchez, Sigifredo
Cruz-González, Adrián
Palmeros-Rojas, Oscar
Gálvez-Romero, José Luis
Bellanti, Joseph A.
Torres, Martha
author_sort Pedraza-Sánchez, Sigifredo
collection PubMed
description Antimicrobial resistance (AMR) is a global health problem that causes more than 1.27 million deaths annually; therefore, it is urgent to focus efforts on solving or reducing this problem. The major causes of AMR are the misuse of antibiotics and antimicrobials in agriculture, veterinary medicine, and human medicine, which favors the selection of drug-resistant microbes. One of the strategies proposed to overcome the problem of AMR is to use polyvalent human immunoglobulin or IVIG. The main advantage of this classic form of passive immunization is its capacity to enhance natural immunity mechanisms to eliminate bacteria, viruses, or fungi safely and physiologically. Experimental data suggest that, for some infections, local administration of IVIG may produce better results with a lower dose than intravenous application. This review presents evidence supporting the use of polyvalent human immunoglobulin in AMR, and the potential and challenges associated with its proposed usage.
format Online
Article
Text
id pubmed-9880058
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98800582023-01-28 Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance Pedraza-Sánchez, Sigifredo Cruz-González, Adrián Palmeros-Rojas, Oscar Gálvez-Romero, José Luis Bellanti, Joseph A. Torres, Martha Front Immunol Immunology Antimicrobial resistance (AMR) is a global health problem that causes more than 1.27 million deaths annually; therefore, it is urgent to focus efforts on solving or reducing this problem. The major causes of AMR are the misuse of antibiotics and antimicrobials in agriculture, veterinary medicine, and human medicine, which favors the selection of drug-resistant microbes. One of the strategies proposed to overcome the problem of AMR is to use polyvalent human immunoglobulin or IVIG. The main advantage of this classic form of passive immunization is its capacity to enhance natural immunity mechanisms to eliminate bacteria, viruses, or fungi safely and physiologically. Experimental data suggest that, for some infections, local administration of IVIG may produce better results with a lower dose than intravenous application. This review presents evidence supporting the use of polyvalent human immunoglobulin in AMR, and the potential and challenges associated with its proposed usage. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9880058/ /pubmed/36713426 http://dx.doi.org/10.3389/fimmu.2022.987231 Text en Copyright © 2023 Pedraza-Sánchez, Cruz-González, Palmeros-Rojas, Gálvez-Romero, Bellanti and Torres https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Pedraza-Sánchez, Sigifredo
Cruz-González, Adrián
Palmeros-Rojas, Oscar
Gálvez-Romero, José Luis
Bellanti, Joseph A.
Torres, Martha
Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance
title Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance
title_full Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance
title_fullStr Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance
title_full_unstemmed Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance
title_short Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance
title_sort polyvalent human immunoglobulin for infectious diseases: potential to circumvent antimicrobial resistance
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880058/
https://www.ncbi.nlm.nih.gov/pubmed/36713426
http://dx.doi.org/10.3389/fimmu.2022.987231
work_keys_str_mv AT pedrazasanchezsigifredo polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance
AT cruzgonzalezadrian polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance
AT palmerosrojasoscar polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance
AT galvezromerojoseluis polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance
AT bellantijosepha polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance
AT torresmartha polyvalenthumanimmunoglobulinforinfectiousdiseasespotentialtocircumventantimicrobialresistance